Verastem traded at $1.10 this Friday June 17th, increasing $0.06 or 5.77 percent since the previous trading session. Looking back, over the last four weeks, Verastem gained 5.98 percent. Over the last 12 months, its price fell by 76.94 percent. Looking ahead, we forecast Verastem to be priced at 1.14 by the end of this quarter and at 1.06 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.10
Daily Change
5.77%
Yearly
-76.94%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 138.28 -0.87 -0.63% 22.24%
AstraZeneca 9,924.00 164.00 1.68% 18.37%
Curis 1.03 0.10 11.18% -86.34%
Cytokinetics 40.58 0.93 2.35% 90.43%
Epizyme 0.69 0.04 5.36% -91.99%
Gilead Sciences 58.53 0.81 1.40% -12.13%
Immunogen 3.71 0.40 12.08% -44.54%
Incyte Corp 71.27 3.23 4.75% -15.11%
Laboratory Of America 226.22 8.08 3.70% -13.06%
Novartis 78.98 -0.23 -0.29% -7.86%
Pfizer 46.53 -0.95 -2.00% 19.89%
Roche Holding 303.35 -0.15 -0.05% -12.89%
TG Therapeutics 4.04 0.30 8.02% -89.24%
Verastem 1.10 0.06 5.77% -76.94%
Ziopharm Oncology 0.87 0.02 2.22% -67.71%

Indexes Price Day Year
USND 10798 152.25 1.43% -23.04%
US2000 1666 15.86 0.96% -25.56%

Verastem
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.